Capsugel Launches enTRinsic Drug Delivery Technology Platform

Capsugel has launched its enTRinsic drug-delivery technology platform. Using pharmaceutically approved enteric polymers, the technology offers full enteric protection without the need for functional coatings and enables targeted release of gastric acid- and heat-sensitive active ingredients in the upper gastrointestinal tract. The new technology platform expands Capsugel’s range of modified- and targeted-release solutions and biotherapeutic formulation offering, and can be used for oral delivery of drugs, including vaccines, proteins, and peptides.

Capsugel says enTRinsic is now globally available for customer projects, following the successful completion of an 18-month lead-user customer-collaboration program that included feasibility studies with new and existing pharmaceutical products. “Our lead-user program confirmed the enteric performance of our enTRinsic technology in multiple applications, as well as the viability of the formulation and manufacture of finished drug product at scale,” said Keith Hutchison, PhD, senior vice-president, Research and Development, Capsugel, in a press release. “We are now excited to move beyond the lead-user program and work with additional customers, while continuing to broaden the application of the technology to encompass gastric resistance, full enteric protection, and varied GI site targeting for an increasingly diverse range of APIs.”

Source: Capsugel